Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme.


Journal

Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698

Informations de publication

Date de publication:
25 02 2020
Historique:
received: 04 10 2019
accepted: 13 02 2020
entrez: 27 2 2020
pubmed: 27 2 2020
medline: 2 2 2021
Statut: epublish

Résumé

Literature reports that mature microRNA (miRNA) can be methylated at adenosine, guanosine and cytosine. However, the molecular mechanisms involved in cytosine methylation of miRNAs have not yet been fully elucidated. Here we investigated the biological role and underlying mechanism of cytosine methylation in miRNAs in glioblastoma multiforme (GBM). RNA immunoprecipitation with the anti-5methylcytosine (5mC) antibody followed by Array, ELISA, dot blot, incorporation of a radio-labelled methyl group in miRNA, and miRNA bisulfite sequencing were perfomred to detect the cytosine methylation in mature miRNA. Cross-Linking immunoprecipiation qPCR, transfection with methylation/unmethylated mimic miRNA, luciferase promoter reporter plasmid, Biotin-tagged 3'UTR/mRNA or miRNA experiments and in vivo assays were used to investigate the role of methylated miRNAs. Finally, the prognostic value of methylated miRNAs was analyzed in a cohorte of GBM pateints. Our study reveals that a significant fraction of miRNAs contains 5mC. Cellular experiments show that DNMT3A/AGO4 methylated miRNAs at cytosine residues inhibit the formation of miRNA/mRNA duplex and leading to the loss of their repressive function towards gene expression. In vivo experiments show that cytosine-methylation of miRNA abolishes the tumor suppressor function of miRNA-181a-5p miRNA for example. Our study also reveals that cytosine-methylation of miRNA-181a-5p results is associated a poor prognosis in GBM patients. Together, our results indicate that the DNMT3A/AGO4-mediated cytosine methylation of miRNA negatively.

Sections du résumé

BACKGROUND
Literature reports that mature microRNA (miRNA) can be methylated at adenosine, guanosine and cytosine. However, the molecular mechanisms involved in cytosine methylation of miRNAs have not yet been fully elucidated. Here we investigated the biological role and underlying mechanism of cytosine methylation in miRNAs in glioblastoma multiforme (GBM).
METHODS
RNA immunoprecipitation with the anti-5methylcytosine (5mC) antibody followed by Array, ELISA, dot blot, incorporation of a radio-labelled methyl group in miRNA, and miRNA bisulfite sequencing were perfomred to detect the cytosine methylation in mature miRNA. Cross-Linking immunoprecipiation qPCR, transfection with methylation/unmethylated mimic miRNA, luciferase promoter reporter plasmid, Biotin-tagged 3'UTR/mRNA or miRNA experiments and in vivo assays were used to investigate the role of methylated miRNAs. Finally, the prognostic value of methylated miRNAs was analyzed in a cohorte of GBM pateints.
RESULTS
Our study reveals that a significant fraction of miRNAs contains 5mC. Cellular experiments show that DNMT3A/AGO4 methylated miRNAs at cytosine residues inhibit the formation of miRNA/mRNA duplex and leading to the loss of their repressive function towards gene expression. In vivo experiments show that cytosine-methylation of miRNA abolishes the tumor suppressor function of miRNA-181a-5p miRNA for example. Our study also reveals that cytosine-methylation of miRNA-181a-5p results is associated a poor prognosis in GBM patients.
CONCLUSION
Together, our results indicate that the DNMT3A/AGO4-mediated cytosine methylation of miRNA negatively.

Identifiants

pubmed: 32098627
doi: 10.1186/s12943-020-01155-z
pii: 10.1186/s12943-020-01155-z
pmc: PMC7041276
doi:

Substances chimiques

AGO4 protein, human 0
Argonaute Proteins 0
Biomarkers, Tumor 0
DNMT3A protein, human 0
Dnmt3a protein, mouse 0
Eukaryotic Initiation Factors 0
MIrn181 microRNA, human 0
MicroRNAs 0
Cytosine 8J337D1HZY
DNA (Cytosine-5-)-Methyltransferases EC 2.1.1.37
DNA Methyltransferase 3A EC 2.1.1.37

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36

Références

Cancer Cell. 2014 Apr 14;25(4):442-54
pubmed: 24656771
PLoS One. 2013 Nov 18;8(11):e79044
pubmed: 24260150
Nucleic Acids Res. 2019 Jan 8;47(D1):D175-D180
pubmed: 30371818
Nucleic Acids Res. 2015 Jul 13;43(12):6112-24
pubmed: 25990724
Biology (Basel). 2016 Jan 06;5(1):
pubmed: 26751487
Methods. 2007 Oct;43(2):162-5
pubmed: 17889804
Carcinogenesis. 2013 Feb;34(2):446-53
pubmed: 23125218
J Biol Chem. 2002 Apr 5;277(14):11735-45
pubmed: 11821381
Front Cell Neurosci. 2013 Dec 25;7:279
pubmed: 24399935
Prog Mol Subcell Biol. 2010;50:1-20
pubmed: 19841878
RNA. 2008 Aug;14(8):1663-70
pubmed: 18567810
Nat Rev Genet. 2007 Feb;8(2):93-103
pubmed: 17230196
Anim Genet. 2014 Aug;45 Suppl 1:15-24
pubmed: 24990588
J Clin Invest. 2013 Jan;123(1):150-63
pubmed: 23241956
Cell Death Dis. 2012 Nov 15;3:e421
pubmed: 23152057
Essays Biochem. 2013;54:17-28
pubmed: 23829524
Epigenetics. 2011 Nov;6(11):1354-61
pubmed: 22048249
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Curr Biol. 2005 Aug 23;15(16):1501-7
pubmed: 16111943
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
Nat Commun. 2019 Aug 29;10(1):3888
pubmed: 31467274
Nucleic Acids Res. 2011 Sep 1;39(16):6845-53
pubmed: 21652644
Nucleic Acids Res. 2015 Jan;43(Database issue):D141-5
pubmed: 25392422
Genome Med. 2013 Dec 30;5(12):111
pubmed: 24373327
J Biol Chem. 2010 Jun 4;285(23):17442-52
pubmed: 20353945
J Cell Biol. 2012 Apr 16;197(2):201-8
pubmed: 22492723
Genome Biol. 2011 Dec 30;12(12):R126
pubmed: 22208850
PLoS One. 2015 Feb 27;10(2):e0118438
pubmed: 25723394
Chembiochem. 2011 Jan 24;12(2):206-22
pubmed: 21243710
Cell Res. 2014 Feb;24(2):177-89
pubmed: 24407421
Mol Cell Biol. 2002 Feb;22(3):704-23
pubmed: 11784849
Front Genet. 2013 Dec 03;4:258
pubmed: 24348513
Cancer Sci. 2012 May;103(5):837-45
pubmed: 22320679
EMBO Rep. 2011 Jul 01;12(7):647-56
pubmed: 21660058
Cell. 2012 Oct 12;151(2):278-88
pubmed: 23063121
Biosci Rep. 2016 Aug 05;36(4):
pubmed: 27364355
BMC Biochem. 2005 Mar 30;6:6
pubmed: 15799776
Nat Rev Cancer. 2013 Jul;13(7):455-65
pubmed: 23783119
Mol Cell. 2019 Jun 20;74(6):1278-1290.e9
pubmed: 31031083
Neurochem Int. 2014 Nov;77:68-77
pubmed: 24937770
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18061-6
pubmed: 22011581
Gene. 2016 Apr 1;579(2):133-8
pubmed: 26743126
Hepatology. 2017 Feb;65(2):529-543
pubmed: 27774652
Science. 2006 Jan 20;311(5759):395-8
pubmed: 16424344
Exp Cell Res. 2013 Feb 1;319(3):173-84
pubmed: 23211718
Genes (Basel). 2017 Sep 05;8(9):
pubmed: 28872587
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Nature. 2015 Mar 26;519(7544):482-5
pubmed: 25799998

Auteurs

Mathilde Cheray (M)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
Present address: Department of Oncology-Pathology, Cancer Centrum Karolinska (CCK), R8:03, Karolinska Institutet, SE-171 76, Stockholm, Sweden.

Amandine Etcheverry (A)

CNRS, UMR 6290, Institut de Génétique et Développement de Rennes (IGdR), F-35043, Rennes, France.
Université Rennes1, UEB, UMS 3480 Biosit, Faculté de Médecine, F-35043, Rennes, France.
Plate-forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043, Rennes, France.
CHU Rennes, Service de Génétique Moléculaire et Génomique, F-35033, Rennes, France.

Camille Jacques (C)

INSERM, UMR 1238, équipe labellisée ligue 2012, 1 Rue Gaston Veil, 44035, Nantes, France.

Romain Pacaud (R)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.

Gwenola Bougras-Cartron (G)

CRCINA, INSERM, Université de Nantes, Nantes, France.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France.
EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France.

Marc Aubry (M)

CNRS, UMR 6290, Institut de Génétique et Développement de Rennes (IGdR), F-35043, Rennes, France.
Université Rennes1, UEB, UMS 3480 Biosit, Faculté de Médecine, F-35043, Rennes, France.
Plate-forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043, Rennes, France.

Florent Denoual (F)

CHU Rennes, Service de Génétique Moléculaire et Génomique, F-35033, Rennes, France.

Pierre Peterlongo (P)

IRISA Inria Rennes Bretagne Atlantique, équipe GenScale, Campus de Beaulieu, 35042, Rennes, France.

Arulraj Nadaradjane (A)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France.
EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France.

Joséphine Briand (J)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France.
EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France.

Farida Akcha (F)

EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France.
Ifremer, Laboratoire d'Ecotoxicologie, Rue de l'Ile d'Yeu, BP21105, cedex 03 44311, . Nantes, France.

Dominique Heymann (D)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.

François M Vallette (FM)

CRCINA, INSERM, Université de Nantes, Nantes, France.
Faculté de Médecine, Université de Nantes, Nantes, France.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.

Jean Mosser (J)

CNRS, UMR 6290, Institut de Génétique et Développement de Rennes (IGdR), F-35043, Rennes, France.
Université Rennes1, UEB, UMS 3480 Biosit, Faculté de Médecine, F-35043, Rennes, France.
Plate-forme Génomique Environnementale et Humaine Biosit, Université Rennes1, F-35043, Rennes, France.
CHU Rennes, Service de Génétique Moléculaire et Génomique, F-35033, Rennes, France.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France.

Benjamin Ory (B)

INSERM, UMR 1238, équipe labellisée ligue 2012, 1 Rue Gaston Veil, 44035, Nantes, France.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France.
EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France.

Pierre-François Cartron (PF)

CRCINA, INSERM, Université de Nantes, Nantes, France. pierre-francois.cartron@inserm.fr.
Faculté de Médecine, Université de Nantes, Nantes, France. pierre-francois.cartron@inserm.fr.
LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France. pierre-francois.cartron@inserm.fr.
LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. pierre-francois.cartron@inserm.fr.
Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Nantes, France. pierre-francois.cartron@inserm.fr.
EpiSAVMEN, Epigenetic consortium Pays de la Loire, Nantes, France. pierre-francois.cartron@inserm.fr.
Institut de Cancérologie de l'Ouest, CRCINA INSERM U1232, Equipe 9 -Apoptose et Progression tumorale, LaBCT, Boulevard du Pr J Monod, 44805, Saint-Herblain, France. pierre-francois.cartron@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH